Core Scientific Inc vs Revvity Inc — how do they compare? Core Scientific Inc trades at $15.28 (market cap $4.94B), while Revvity Inc trades at $155.03 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 3.4× Core Scientific Inc's market cap, and Revvity Inc pays a 0.18% dividend while Core Scientific Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Core Scientific Inc for 20 Days and Revvity Inc for 12 Days on average.
| CORZ | RVTY | |
|---|---|---|
Market Cap | $4.94B | $16.98B |
Volume | 15,630,800 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $29.16 | $157.36 |
52-Week Low | $13.57 | $82.26 |
Typical Hold Time | 20 Days | 12 Days |
Enterprise Value | $7.46B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Core Scientific (CORZ) trades at $15.30, down 4.02% today amid bearish technical signals and negative earnings momentum. The stock faces fundamental challenges with a net income margin of -324.9% and three consecutive quarterly earnings misses. However, analyst sentiment remains overwhelmingly positive with 86% buy ratings and a $32.75 consensus price target, while recent executive appointments and AI infrastructure developments provide potential catalysts.
Despite current financial struggles, CORZ shows potential through its pivot to AI data center services and strong institutional support. Key risks include persistent negative profitability, high capital expenditures, and cryptocurrency market volatility. The significant gap between current price and analyst targets suggests upside potential if the company executes its AI infrastructure strategy successfully.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Core Scientific provides digital infrastructure for Bitcoin mining and high-performance computing (HPC). It operates purpose-built data centers to support digital asset production and AI-related workloads.
Read more on CORZ →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →